Company profile: DJS Antibodies
1.1 - Company Overview
Company description
- Provider of antibody therapeutics and discovery technology targeting GPCRs to treat chronic inflammatory and fibrotic diseases. Offers HEPTAD, a proprietary platform to discover functional, first-in-class antibodies for complex protein targets; DJS 001, a first-in-class program for myeloid cell driven inflammatory disease; and DJS 002, a monoclonal antibody for fibrotic diseases without off-target side effects.
Products and services
- HEPTAD: A proprietary discovery platform targeting GPCRs that architects functional antibodies to complex protein targets, enabling first-in-class therapeutics against previously intractable disease targets
- DJS 001: A first-in-class program targeting myeloid cell‑driven inflammatory disease with a molecule engineered to precisely address myeloid cell‑driven pathologies
- DJS 002: A GPCR-targeted monoclonal antibody for fibrotic diseases that delivers a specific approach without off‑target side effects for focused therapeutic activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DJS Antibodies
Bliss Biopharma
HQ: China
Website
- Description: Provider of tumor-targeting and immunotherapy therapeutics, focused on antibody-drug conjugates (ADCs). Offers BB-1701, an anti-HER2 ADC in international multi-center trials for HER2-positive solid tumors, and a diverse ADC pipeline in preclinical and clinical stages. Operates in-house, GMP-compliant antibody and ADC manufacturing to support clinical development and early commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bliss Biopharma company profile →
SciFluor
HQ: United States
Website
- Description: Provider of fluorination technologies that improve drug properties, such as metabolic stability and potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciFluor company profile →
Vicore Pharma
HQ: Sweden
Website
- Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicore Pharma company profile →
Tolmar
HQ: United States
Website
- Description: Provider of pharmaceutical research, development, manufacturing and commercial operations, delivering proprietary and generic products in dermatology, oncology, and dental therapeutics, including ELIGARD (leuprolide acetate for prostate cancer), Fensolvi (leuprolide acetate for central precocious puberty), and topical dermatology generics—ointments, creams, gels, and lotions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tolmar company profile →
Allegro Ophthalmics
HQ: United States
Website
- Description: Provider of integrin inhibition therapy focused on retinal diseases, including Risuteganib (Luminate), an investigational compound targeting mitochondrial dysfunction and oxidative stress to restore retinal homeostasis for intermediate dry age-related macular degeneration, and ALG-1007, a topical mitochondrial stabilizer in development for dry eye disease with promising clinical trial results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allegro Ophthalmics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DJS Antibodies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DJS Antibodies
2.2 - Growth funds investing in similar companies to DJS Antibodies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DJS Antibodies
4.2 - Public trading comparable groups for DJS Antibodies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →